2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
24
Kidney Neoplasms
8
von Hippel-Lindau Disease
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pheochromocytoma
2
Paraganglioma
2
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Metastatic Castration-Resistant Prostate Cancer
1
Hemangioblastoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
Everolimus
9
Temozolomide
7
Sunitinib
7
Specimen Handling
4
Octreotide
4
Magnetic Resonance Spectroscopy
4
Fluorouracil
4
Capecitabine
4
lutetium Lu 177 dotatate
3
Leucovorin
3
sargramostim
2
montanide ISA 51
2
incomplete Freund's adjuvant
2
cabozantinib
2
Thalidomide
2
Streptozocin
2
Sorafenib
2
Oxaliplatin
2
Irinotecan
2
Injections
2
Endoscopic Ultrasound-Guided Fine Needle Aspiration
2
Doxorubicin
2
Cytoreduction Surgical Procedures
2
Colony-Stimulating Factors
2
Bevacizumab
2
surufatinib
1
sapanisertib
1
recombinant interferon alpha 2b-like protein
1
pentetreotide
1
pasireotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoma, Islet Cell
×
belzutifan
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA